Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2022

View Archived Issues

CFB inhibitors identified by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine

ScinnoHub Pharmaceutical discovers plasmin inhibitors

Discovery of novel candidates for the treatment of Chagas disease

Impact Biomedical announces development of Quantum antihistamine

SBIR grant supports STRM.BIO's development of EV technology as gene therapy delivery platform

ExcellGene plays role in CEPI-funded consortium to advance new vaccine concept for SARS-CoV-2

Medshine Discovery describes new complement factor B inhibitors

C-65780 stabilizes voltage-gated sodium channels and produces pain relief in vivo

Suzhou Zelgen Biosciences identifies new aryl hydrocarbon receptor antagonists

New MAT2A inhibitors discovered at Jiangsu Simcere Pharmaceutical R&D

Monoclonal antibody pairs "zipper" to target cancer

Amubarvimab/romlusevimab retains neutralizing activity against live Omicron subvariants

Vitamin B6 benzohydrazide platinum(II) complexes overcome cisplatin resistance in tumors

ZyVersa receives grant to assess potential of IC-100 to block neuroinflammation in Parkinson's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...